Shares of UnitedHealth Group plunged more than 18% on Thursday following a report that the Justice Department is conducting a criminal investigation into the health-care giant over possible Medicare fraud.The DOJ is focusing on the company's Medicare Advantage business practices, but the exact nature of the potential criminal allegations is unclear, the Wall Street Journal reported late Wednesday, citing people familiar with the matter. In a statement, UnitedHealth Group said the Justice Department has not ...

UnitedHealth Group shares fell more than 15% in early morning trading on Thursday, after The Wall Street Journal reported that the U.S. Department of Justice was investigating the company for potential Medicare fraud. The latest news adds to the health insurer's litany of woes, including multiple government inquiries, a sudden change in top leadership and a pulled outlook in the face of soaring medical costs.Investors and analysts noted that while details on the investigation were limited, they did heighten ...

UnitedHealth Group (NYSE: UNH ) stock has been a dog lately, as it hasn't performed this poorly since 2008, but I think it's a dog worth petting. The last time I wrote about UNH was in October. II prefer to look for GARP (growth at a reasonable price) stocks but also look for opportunities everywhere else. I don't have a specified time horizon. I invest in a stock for as long as my thesis holds true, and I get out when the facts change. In addition, I've developed market-beating algorithms with Python that ...

CHONGQING, CHINA - APRIL 14: In this photo illustration, the UnitedHealthcare logo is displayed on a ... More smartphone screen, with the company's latest stock price performance and candlestick chart visible in the background, reflecting market volatility and investor sentiment on April 14, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images) Once a stalwart of healthcare investing, UnitedHealth Group (NYSE: UNH) has recently experienced a significant downturn. Its rapid stock price decline has led ...

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UnitedHealth Group Incorporated (NYSE: UNH) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in UnitedHealth you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/unitedhealth-group-incorporated. Investors have until July 7, 2025, to ask the ...

I am rating Oscar Health, Inc. (NYSE: OSCR ) as a hold due to a proposed steep budget cut of $163 billion in the 2026 budget estimates. The Health and Human Services (HHS) cut is estimated to be $33.3 billion, an $18 billion cutFirst Principles Partners is an equity research analyst specializing in technology, innovation, and sustainability investment. My unique approach, "First Principles," involves breaking down complex problems to their most basic elements in terms of financial and technology, enabling m ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Elevance Health, Inc. common stock during the specified Class Period, indicating potential misrepresentation by the company regarding Medicaid cost trends and premium negotiations [1][5]. Group 1: Class Action Details - The class action is for investors who purchased Elevance Health common stock between April 18, 2024, and October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. Group 2: Allegations Against Elevance Health - The lawsuit claims that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance for 2024 [5]. - It is alleged that the company assured investors that rising Medicaid expenses were adequately reflected in its guidance, while in reality, the acuity and utilization of Medicaid members were increasing significantly [5]. - The lawsuit suggests that the members being removed from Medicaid were healthier than those who remained, which was not accounted for in Elevance's rate negotiations or financial forecasts [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

CVS Health (CVS) shares have rallied nearly 38% so far this month, driven by the company’s stronger-than-expected first-quarter 2025 results. Despite concerns over the company’s decision to implement widespread store closures due to new Pharmacy Benefit Management (PBM) reform legislation, market sentiment remains positive. Investors are encouraged by the robust performance of CVS Health Care Benefits segment, which benefited from favorable prior-year development and improved Medicare performance. The margi ...

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for alleged violations of federal securities laws during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Elevance misrepresented its monitoring of cost trends related to the Medicaid redetermination process and assured investors that premium rates were sufficient to manage risks associated with Medicaid patients [3]. - It is alleged that while Elevance acknowledged rising Medicaid expenses, the company misled investors by stating that these costs were adequately reflected in its financial guidance for 2024 [3]. - The complaint highlights that the redetermination process led to a significant increase in the acuity and utilization of Medicaid members, contradicting Elevance's representations regarding its financial outlook [3]. Group 2: Investor Participation - Investors who purchased Elevance securities during the Class Period are encouraged to join the lawsuit, with a deadline of July 11, 2025, to request lead plaintiff status [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the lawsuit is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Group 1: Palantir (PLTR) - Palantir experienced significant growth with sales increasing by 39% year-over-year, raising its current year sales outlook to an estimated $3.9 billion, suggesting a 41% growth year-over-year [2][4] - The customer count grew nearly 40% year-over-year and 8% sequentially, with the highest U.S. commercial total contract value of $810 million, reflecting a 180% year-over-year increase [4] - Analysts have revised their EPS expectations upward, indicating a positive outlook for near-term share performance [4] Group 2: Centene (CNC) - Centene reported adjusted EPS of $2.90 and sales of $46.6 billion, exceeding consensus estimates with earnings up 28% year-over-year [6] - The company raised its 2025 premium and service revenues guidance by $6.0 billion, reflecting a 17% year-over-year improvement [6] - Following the guidance upgrade, analysts expect Centene to post $178.7 billion in revenues for the current fiscal year [9] Group 3: Cboe Global Markets (CBOE) - Cboe posted record adjusted EPS of $2.37, up 21% year-over-year, and record net revenue of $562.5 million, up 13% year-over-year [11] - The company reported record Options net revenue of $352.4 million, reflecting a 15% year-over-year increase, and global FX net revenue of $21.3 million, up 16% year-over-year [12] - Analysts have revised their earnings expectations higher, indicating a favorable near-term earnings outlook [14]